Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home
16 items matching your search terms.
Filter the results.
Item type














New items since



Sort by relevance · date (newest first) · alphabetically
Pignone - Eligibility for aspirin for primary prevention in men increases when cancer mortality benefit added
by William Shawn Davis (wishda) published Jun 04, 2013 last modified Jun 06, 2013 09:07 AM — filed under:
While aspirin has been shown to be effective in preventing heart attacks in men, it also increases the risk of gastrointestinal bleeding and possibly stroke, even at low doses. As such, national guidelines suggest that aspirin be used for prevention only in men at higher risk for cardiovascular events, so that the benefits of aspirin are greater than its adverse effects.
Located in News
RNA Diagnostic Test from Paraffin Improves Lung Cancer Diagnosis Over Routine Microscopic Evaluation Alone
by William Shawn Davis (wishda) published Jul 16, 2013 last modified Jul 16, 2013 09:17 AM — filed under:
Knowing what type of lung cancer a patient has is critical to determine which drug will work best and which therapies are safest in the era of personalized medicine. Key to making that judgment is an adequate tumor specimen for the pathologist to determine the tumor’s histology, a molecular description of a tumor based on the appearance of cells under a microscope. But not all specimens are perfect, and are sometimes so complex that a definitive diagnosis presents a challenge.
Located in News
The value of randomized clinical trials in radiation oncology clinical practice
by William Shawn Davis (wishda) published May 29, 2013 last modified Jun 10, 2013 03:20 PM — filed under:
Cancer patients, physicians and insurers want to be sure that whatever therapy is recommended and provided to patients is based on evidence, preferably results from randomized clinical trials. But are there enough clinical trials data to provide this level of confidence?
Located in News
UNC scientists identify possible KRAS downstream target for pancreatic cancer therapy
by Megan Fazekas-King (fazekask) published May 28, 2013 last modified Jun 13, 2013 02:22 PM — filed under:
While the mutated KRAS oncogene is associated with many cancers, it has not yet been successfully targeted by a therapeutic agent. Scientists are trying to find another way to target the gene by blocking signals from another protein downstream.
Located in News
UNC scientists identify possible KRAS downstream target for pancreatic cancer therapy
by William Shawn Davis (wishda) published May 28, 2013 last modified May 28, 2013 01:55 PM — filed under:
While the mutated KRAS oncogene is associated with many cancers, it has not yet been successfully targeted by a therapeutic agent. Scientists are trying to find another way to target the gene by blocking signals from another protein downstream.
Located in Old top news stories
Yeh and Johnson awarded Lustgarten Foundation grant for pancreatic cancer
by William Shawn Davis (wishda) published Jun 28, 2013 last modified Jun 28, 2013 12:37 PM — filed under:
Jen Jen Yeh, MD, and Gary Johnson, PhD, were awarded a $326,708.00 grant from the Lustgarten Foundation for a one-year pilot study to investigate the kinome landscape of pancreatic cancer.
Located in News